Get Connected:

 

Latest News

Trending News Today: Illinois Lawmakers Push for Medical Marijuana as Opioid Alternative
Top news of the day from across the health care landscape
 
Patients with rare diseases often face a difficult and long diagnosis and treatment process. 
FDA officials have approved the first generic versions of buprenorphine and naloxone (Suboxone, Mylan Technologies Inc and Dr. Reddy's Laboratories SA) sublingual film to treat opioid dependence.
Top news of the week from The American Journal of Pharmacy Benefits.
Top news of the day from across the health care landscape
 
Top news of the day from across the health care landscape
 
As the age of technology continues to blossom, people are spending upwards of 10 hours per day looking at screens—4 hours longer than recommended by physicians.
Top news of the day from across the health care landscape
View More >

From the Journals

New proposed rules for the Medicare Part D drug program could affect the manner in which pharmacy benefit managers administer the program and could impact profitability.
Healthcare stakeholders must evaluate how to use resources more efficiently as it has become clear that driving down prices in one segment of care has not improved medical outcomes for the majority of patients.
This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.
An estimation and comparison of the cost of home phototherapy versus biologics over a 3-year time horizon in patients with moderate-to-severe plaque psoriasis.
The study found no mean difference in all-cause healthcare costs for patients with newly diagnosed nonvalvular atrial fibrillation initiating treatment with dabigatran versus warfarin.
Buprenorphine treatment with and without induction was found to decrease costs and utilization in opioid-dependent benefciaries.
Focusing on cost alone could diminish the vital service aspects behind successfully caring for a patient in a specialty pharmacy.
Upcoming Partner Events